{
    "id": "d29f980a-e696-4020-8bf9-8f81016c0699",
    "indications": {
        "text": "escitalopram oral solution indicated treatment : major depressive disorder ( mdd ) adults pediatric patients 12 years age older . generalized anxiety disorder ( gad ) adults . additional pediatric information approved abbvie inc. \u2019 lexapro ( escitalopram ) oral solution . however , due abbvie inc. \u2019 marketing exclusivity rights , product labeled information .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication population recommended mdd adults ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily mdd pediatric patients 12 years older ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily gad adults ( 2.2 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily additional benefits seen 20 mg daily . ( 2.1 ) administer daily , morning evening , without food . ( 2.3 ) elderly patients : recommended 10 mg daily . ( 2.4 ) hepatic impairment : recommended 10 mg daily . ( 2.4 , 8.6 ) discontinuing escitalopram oral solution , reduce dose gradually whenever possible . ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "oral solution escitalopram oral solution , usp , equivalent 5 mg base/5 ml , clear colorless pale yellow , peppermint flavored solution , available 240 ml ; ndc 65162-705-88. storage handling store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "escitalopram oxalate contraindicated patients : taking maois escitalopram oxalate within 14 days stopping treatment escitalopram oxalate increased risk serotonin syndrome . escitalopram oxalate within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.7 ) ( 5.2 ) ] . starting escitalopram oxalate patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.6 ) ( 5.2 ) ] . taking pimozide [ ( 7 ) ] . hypersensitivity escitalopram citalopram inactive ingredients escitalopram oral solution .",
    "ingredients": [
        {
            "name": "ESCITALOPRAM OXALATE",
            "code": "5U85DBW7LO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36791"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "MALIC ACID",
            "code": "817L1N4CKP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6650"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PEPPERMINT",
            "code": "V95R5KMY2B",
            "drugbank_id": "https://go.drugbank.com/drugs/DB10984"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        }
    ],
    "organization": "Amneal Pharmaceuticals LLC",
    "name": "Escitalopram Oxalate",
    "effectiveTime": "20250422",
    "indications_original": "Escitalopram oral solution is indicated for the treatment of:\n                  \n                     major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older.\n                     generalized anxiety disorder (GAD) in adults.\n                  \n                  \n                     Additional pediatric use information is approved for AbbVie Inc.\u2019s LEXAPRO (escitalopram) oral solution. However, due to AbbVie Inc.\u2019s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "Indication and Population Recommended Dosage MDD in Adults (2.1) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older (2.1) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults (2.2) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily. (2.1) Administer once daily, morning or evening, with or without food. (2.3) Elderly patients: recommended dosage is 10 mg once daily. (2.4) Hepatic impairment: recommended dosage is 10 mg once daily. (2.4 , 8.6 ) When discontinuing escitalopram oral solution, reduce dose gradually whenever possible. (2.5)",
    "warningsAndPrecautions_original": "Oral Solution\n                  \n                  Escitalopram oral solution, USP, equivalent 5 mg base/5 mL, is a clear colorless to pale yellow, peppermint flavored solution, available as\u00a0240 mL; NDC\u00a0 65162-705-88.\n                  \n                     \n                        Storage and Handling\n                     \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Escitalopram oxalate is contraindicated in patients:\n                  \n                     taking MAOIs with escitalopram oxalate or within 14 days of stopping treatment with escitalopram oxalate because of an increased risk of serotonin syndrome. The use of escitalopram oxalate within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.7)\n                        \u00a0and\u00a0\n                           Warnings and Precautions (5.2)]. Starting escitalopram oxalate in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.6)\u00a0and\u00a0\n                           Warnings and Precautions (5.2)].\n                  \n                  \n                     taking pimozide [see Drug Interactions (7)].\n                     with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram oral solution.",
    "drug": [
        {
            "name": "Escitalopram Oxalate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_36791"
        }
    ]
}